No photo of Joop de Langen

View Scopus Profile

Joop de Langen

DRS.

20062019
If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2006 2019

ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib

Thunnissen, E., Lissenberg-Witte, B. I., van den Heuvel, M. M., Monkhorst, K., Skov, B. G., Sørensen, J. B., Mellemgaard, A., Dingemans, A. M. C., Speel, E. J. M., de Langen, A. J., Hashemi, S. M. S., Bahce, I., van der Drift, M. A., Looijen-Salamon, M. G., Gosney, J., Postmus, P. E., Samii, S. M. S., Duplaquet, F., Weynand, B., Durando, X. & 15 othersPenault-Llorca, F., Finn, S., Grady, A. O., Oz, B., Akyurek, N., Buettner, R., Wolf, J., Bubendorf, L., Duin, S., Marondel, I., Heukamp, L. C., Timens, W., Schuuring, E. M. D., Pauwels, P. & Smit, E. F., 2019, In : Lung Cancer. 138, p. 13-18 6 p.

Research output: Contribution to journal › Article › Academic › peer-review

Effect of Pembrolizumab after Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients with Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial

Theelen, W. S. M. E., Peulen, H. M. U., Lalezari, F., van der Noort, V., de Vries, J. F., Aerts, J. G. J. V., Dumoulin, D. W., Bahce, I., Niemeijer, A-L. N., de Langen, A. J., Monkhorst, K. & Baas, P., 2019, In : JAMA Oncology.

Research output: Contribution to journal › Article › Academic › peer-review

Repeatability of [ 18 F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients

Kolinger, G. D., Vállez García, D., Kramer, G. M., Frings, V., Smit, E. F., de Langen, A. J., Dierckx, R. A. J. O., Hoekstra, O. S. & Boellaard, R., 2019, In : EJNMMI Research. 9, 14.

Research output: Contribution to journal › Article › Academic › peer-review

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs

van der Velden, D. L., Hoes, L. R., van der Wijngaart, H., van Berge Henegouwen, J. M., van Werkhoven, E., Roepman, P., Schilsky, R. L., de Leng, W. W. J., Huitema, A. D. R., Nuijen, B., Nederlof, P. M., van Herpen, C. M. L., de Groot, D. J. A., Devriese, L. A., Hoeben, A., de Jonge, M. J. A., Chalabi, M., Smit, E. F., de Langen, A. J., Mehra, N. & 7 othersLabots, M., Kapiteijn, E., Sleijfer, S., Cuppen, E., Verheul, H. M. W., Gelderblom, H. & Voest, E. E., 30 Sep 2019, In : Nature.

Research output: Contribution to journal › Article › Academic › peer-review

Treatment of oncogene-driven non-small cell lung cancer

Kastelijn, E. A., de Langen, A. J. & Peters, B. J. M., 2019, In : Current opinion in pulmonary medicine. 25, 3, p. 300-307

Research output: Contribution to journal › Article › Academic › peer-review